IceCure Medical announced that it has received a written notice from Nasdaq indicating that the company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550, which requires listed securities to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810, the company has been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement. The notice has no immediate effect on the company’s Nasdaq listing or the trading of its ordinary shares, and during the grace period, as may be extended, the company’s ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol (ICCM).
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICCM:
- IceCure Medical Promotes Shay Levav to COO Amid U.S. Expansion
- IceCure Medical names Shay Levav as COO
- IceCure’s Cryoablation System Shows Promising Results in Lung Cancer Treatment
- IceCure Medical Announces Termination of VP of Operations
- Buy Rating for Icecure Medical: FDA Approval and Strategic Initiatives Drive Growth Potential